GSK Pharma schedules November 3 results as GSK Pharma stock awaits figures

Published on 10/25/2026 at 02:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK Pharma posted 15.7 percent revenue growth in the first quarter. GSK Pharma stock had an INR 407.4 billion market value on October 23, 2026.

Upcoming results and operating figures

The board will review second-quarter and half-year results on November 3, 2026.
First-quarter revenue rose 15.7 percent to INR 982.20 crore.
GSK Pharma had an INR 407.4 billion market capitalization on October 23, 2026.

GSK Pharma, INE159A01016, Illustration mit AI erstellt.

GSK Pharma (INE159A01016) reported first-quarter fiscal 2027 revenue of INR 982.20 crore, up 15.7 percent year over year, while net profit also rose 15.7 percent to INR 237.18 crore, according to Univest. The latest corporate catalyst is a board meeting scheduled for November 3, 2026, to consider unaudited second-quarter and half-year results for the period ended September 30, 2026, as reported by Gunpowder Alerts.

Three dated results markers

On May 13, 2026, GSK Pharma reported fourth-quarter net profit of INR 275 crore, according to InCred Money. On August 3, 2026, first-quarter revenue reached INR 924 crore and profit after tax rose 24 percent, the same source reported. On October 13, 2026, the company notified the exchanges of the November 3 results meeting, covering the second quarter and half year ended September 30, 2026.

What does growth mean for margins?

The operating picture combines faster first-quarter sales with a 38.60 percent operating margin for fiscal year 2026, while full-year revenue reached INR 3,967.03 crore and net profit stood at INR 1,035.98 crore, according to Univest. The comparison matters because fiscal-year revenue was 1.8 percent higher than fiscal year 2025, while net profit increased 11.7 percent. The November release will show whether the first-quarter growth rate carried into the September quarter.

Dates investors can mark

November 3, 2026 is the next substantiated reporting date for the second quarter and half year. December 1, 2026 is the effective date for Bhushan Akshikar's renewed managing-director term, according to StockFin.

Market value before the results

GSK Pharma had an INR 407.4 billion market capitalization on October 23, 2026. Its 52-week range was INR 2,088.00 to INR 3,121.10, and the stock price was INR 2,404.80 at the latest dated close cited by Equitymaster. The company operates in branded medicines and vaccines in India, with respiratory, oncology, HIV and infectious-disease activities highlighted on its GSK India investor page.